Strides Pharma Reports Strong Q3 Results: Revenue and Profit Surge

Strides Pharma Science Ltd. has announced impressive financial results for the December quarter, with consolidated revenue from operations reaching ₹11.54 billion, marking a significant increase compared to the previous year. The company also reported a net profit of ₹879.5 million, a remarkable turnaround from last year's loss. This performance highlights Strides' effective strategies post-demerger, positioning it well for future growth as it aims for a FY25 U.S. business revenue target of $275 million to $290 million. The stock surged 5% following the announcement, reflecting investor confidence in the company's trajectory. 
Source: CNBC TV18